In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Diagnosis & Disease Information
First-Line Regimens With Endocrine Therapy Show Benefits in Breast Cancer
Findings seen among subgroup of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Xeloda Labeling Updated Under FDA’s New Program for Older Oncology Drugs
Project Renewal is an Oncology Center of Excellence initiative that aims to update the labeling information for certain older oncology drugs.
Platinum Chemo “Should Be Standard” for Younger Patients With TNBC
Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.
Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer
Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.
Germline PVs in BRCA1/2, CHEK2 Linked to Higher Risk of Contralateral Breast Cancer
Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.
Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Ribociclib Plus ET Outperforms Chemo in HR+/HER2− Advanced Breast Cancer
Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.
Older Patients With Metastatic Breast Cancer Often Do Not Receive First-Line Systemic Therapy
A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.
